Evidence map›Paper›PMID 36593610›Full record

ArticleBMJ case reports2022

Two rare cases of bullous pemphigoid associated with immune checkpoint inhibitors.

Anika Mazumder, Kavita Darji, Kristin Smith, Mary Guo

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Anika MazumderSaint Louis University School of Medicine, Saint Louis, Missouri, USA anika.mazumder@health.slu.edu.ORCID http://orcid.org/0000-0002-2596-3204
Kavita DarjiDepartment of Dermatology, Saint Louis University School of Medicine, Saint Louis, Missouri, USA.
Kristin SmithDepartment of Dermatology, Saint Louis University School of Medicine, Saint Louis, Missouri, USA.
Mary GuoDepartment of Dermatology, Saint Louis University School of Medicine, Saint Louis, Missouri, USA.
Saint Louis University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bullous pemphigoid is a rare and severe adverse reaction to immune-checkpoint inhibitors that can be life-threatening. Here, we present two cases of bullous pemphigoid secondary to nivolumab and ipilimumab+nivolumab therapy, respectively. Both cases presented months after discontinuation of immunotherapy. Our first case highlights the life-threatening nature of bullous pemphigoid due to its potential to cause laryngeal oedema. Our second case illustrates that cytotoxic T-lymphocyte-associated protein-4 inhibitors can rarely lead to bullous pemphigoid, in addition to programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors. Both cases emphasise the importance of skin examinations and dermatological follow-up for patients during and even after discontinuation of immunotherapy.

Indexed as

NivolumabPemphigoid, BullousAntibodies, Monoclonal, HumanizedHumansImmune Checkpoint InhibitorsAntibodies, Monoclonal, HumanizedImmune Checkpoint InhibitorsNivolumabCancer interventionDermatologyOncologyUnwanted effects / adverse reactions

Identifiers

PMID36593610
PMCPMC9730361
OpenAlexW4311165579

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.